Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753816 · ClinicalTrials.gov registry record · NA
TXA Study in Major Burn Surgery
A NA study, sponsored by Corewell Health West.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02753816 is a NA study that was terminated before completion, run by Corewell Health West. The registered enrollment target is 25 participants.
The verdict
NCT02753816, a NA study, was terminated before completion, sponsored by Corewell Health West.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. Investigators believe tranexamic acid may possibly decrease bleeding related to major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your stay. In this study, prior to each surgical procedure to treat the participants burn injury, the participant will receive either the drug tranexamic acid or placebo. The placebo is a liquid that looks like the tranexamic acid medicine, but does not have any active ingredient in it. In this study, both the tranexamic acid and the placebo are considered research.
Interventions
- DRUG Tranexamic Acid
- DRUG Placebo Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-12-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02753816
The ClinicalTrials.gov registry entry for NCT02753816 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02753816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02753816 about?
NCT02753816 is a clinical study titled "TXA Study in Major Burn Surgery". Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergo...
What is the current status of trial NCT02753816?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2016-04. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT02753816?
The interventions under investigation include: Tranexamic Acid (DRUG), Placebo Comparator (DRUG).
Who is sponsoring clinical trial NCT02753816?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.